reason report
withdrew prior guidanc cite uncertainti
impact dont think pull guidanc
much surpris move clearli upset investor
would expect stock admit
much galvan stock near term
await event later year includ data present
medic meet fall adcom pdufa
novemb made adjust financi model
includ lower revenu expens result lower
ep forecast
increas revenu account rebound demand also
lower spend launch help
increas ep forecast maintain mp
rate pt
takeaway manag point strong
vivitrol aristada manag believ due real sale
rather advanc stock pull-through
seen pharma compani report far
manag indic use digit engag
telehealth virtual educ physician patient servic etc
mitig disrupt note weak product
shipment recent specif indict vivitrol rx april
lighter previou growth expect assum
rang thu impli rx vivitrol
look impact aristada manag
comment unemploy rise could lead greater share
sale go medicaid would increas regard
manag indic process fda
move along expect fda plan hold adcom
note think due issu file
rather discuss weight gain/metabol benefit guidanc
withdrawn compani expect updat
anytim soon due lack clariti impact sale
manag plan monitor situat care adjust
spend accordingli goal still much focu bottom
line pipelin progress expect manag
seen trial enrol slowdown tri shift
cro work less geographi product
well hdac histon deacetylas asset
sotp cash flow
discount rate
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
detail product highlight confer call
vivitrol solid sale yoy driven unit growth gross-to-net
slightli vs asp sequenti decreas net sale
larg driven season inventori drawdown slightli higher manag indic
factori shipment lower monthli inventori vs dec unit
sale vs inventori build physician prescrib account increas
yoy robust growth top state net sale state grow
yoy vivitrol guidanc rescind manag note last
week vivitrol new patient start sale pressur driven closur
addict treatment center decreas access detoxif servic in-hospit
compet effort decreas patient desir interact health care site
mitig neg trend compani increas outpati servic via new partnership
albertson achiev favor reimburs far
aristada strong net sale yoy driven unit growth slightli
higher vs asp underli rx data show robust yoy
growth all-tim high nrx market share long-act inject lai march
anoth new high new-to-brand rx feb came dose
manag indic demonstr strateg focu dose increas awar
initio get traction guidanc rescind well manag made
increment comment compar vivitrol aristada less vulner weak new
patient start sale observ flatten weekli rx wholesal shipment
inventori unit vs dec april note psychiatri may benefit
fact physician adopt telemedicin higher rate vs specialti
nda review remain track manag announc fda plan hold
adcom fall involv divis launch prep ramp compani
evalu differ launch scenario focu remain increas awar salesforc
plan obtain favor market access manag work price market access
assum price rang recent launch brand antipsychot
rang manag plan add rep psychiatr salesforc launch
lower assumpt
regard hdac asset manag note patient enrol on-going
studi manag see slow-down april due
adapt manag plan activ select ex-u site asia pacif europ
frequent commun trial investig maintain treatment continu reduc in-
person site visit hdac inhibitor platform track compani geograph shift
work done well maintain work progress
believ stop compani base mix efficaci
data opioid concern importantli neg feedback fda
adcom fda
believ expect high physician like
product believ reimburs difficult new brand without
novel moa highli gener market
dont agre bullish stanc investor base busi
justifi current valuat whole compani thu pipelin view
pt base sotp analysi forecast cash flow
earlier-than-expect deterior royalti
flatten decreas growth trajectori vivitrol aristada
lower vumer royalti revenu due earlier-than-expect gener
entri tecfidera
neg efficacy/safeti data
schizophrenia
schizophrenia
immuno-oncolog present efficaci data
schizophrenia
schizophrenia
bipolar disord top-lin data young patient earli ill phase
head head
 incom statement million except per-shar guidanc conf guidanc conf profit guidanc conf guidanc conf acquir intang guidanc conf non-oper guidanc conf net incom guidanc conf net incom guidanc conf share basic ep basic guidanc conf share ep guidanc conf share ep compani report svb leerink llc estimatesco guidanc conf ep alkerm plc
sale ustot growth rate per rx price per rx average monthli growth rate growth rate total total growth per rx net per rx growth per rx net per rx growth net adjust per rx net growth rate growth rate alkerm plc
sale growth rate trx add uncaptur per rx gross per rx gross per rx gross per rx gross increas total trx total trx total trx total trx per rx gross per rx average monthli growth rate growth rate net per rx growth rate growth rate alkerm plc
million except per-shar royalti revenuesj partner long-act antipsychoticsinvega sustenna/xeplion/trinza/trevictau sustenna growth rate us sustenna royaltiesu trinza growth rate us trinza royaltiesu sustenna/trinza growth sustenna growth rate ou sustenna royalties trinza growth rate ou trinza royalties sustenna/trinza growth sustenna/trinza growth rate invega sustenna/trinza growth constau growth growth growth manufactur royalti rate sale royalti rate risperd consta partner growth alkerm plc
 balanc sheet million except per-shar asset receiv expens current plant asset tax stockhold equitycurr liabilitiesaccount payabl accru revenue/oth short-term debt current portion lt current liabilitieslong term revenu long long term non-curr equitycommon stock stock paid-in comprehens stockhold liabil stockhold plc
 statement million except per-shar oper activitiesnet compens co co long term incom oper asset liabil work use oper invest activitiescapit expendititur sale equipment/financi use invest financ activitieschang common stock tax benefit stock-bas purchas risperd consta note long-term debt capit leas use financ equival begin equival end plc
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori plc
leerink place outperform rate octob
creat bluematrix
pt base sotp analysi forecast cash flow discount rate
risk valuat
earlier-than-expect deterior royalti
flatten decreas growth trajectori vivitrol aristada
lower vumer royalti revenu due earlier-than-expect gener entri tecfidera
neg efficacy/safeti data
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target appli price-to-earnings
multipl -- stabl price-to-earnings multipl ep estim -- ep estim
arriv valuat assum stabl multipl gener rel act defens
broader macroeconom downturn see seem like continu
least time beyond
risk valuat
risk includ failur success integr auri potenti futur acquisit failur resolv
outstand consum consent decre success re-launch product product recal failur
advanc late-stag pipelin success launch new product protract recoveri procedur volum
trend lack real macroeconom recoveri
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
